FDA accepts Merck's MK-3475 BLA for review

[News]

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) for MK-3475, Merck's investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab.

More... (http://www.news-medical.net/news/20140506/FDA-accepts-Mercks-MK-3475-BLA-for-review.aspx)